The transaction will contain a complete mixture consideration of ₹1,250 crore, Novartis India stated in an trade submitting.
Following the board’s approval at its assembly held on September 7, Novartis India executed an asset buy settlement and trademark task deeds with Pfizer Inc. and Pfizer Merchandise Inc. for the transaction.
Below the settlement, Pfizer will assign the Minipress and Minipres emblems registered in India, together with sure associated mental property rights, to Novartis India. The signing and shutting of the transaction will happen concurrently, the corporate stated.
In accordance with IQVIA MAT July 2026 information cited by Novartis India, Minipress XL recorded income of ₹228.6 crore and grew at a compound annual progress price of 6.3% over the previous 4 years. The class, in the meantime, expanded at a CAGR of 9% throughout the identical interval.
Minipress XL, which comprises prazosin, is primarily utilized in India for the therapy of hypertension, or hypertension, and for managing urinary signs related to benign prostatic hyperplasia (BPH).
Pfizer to discontinue Minipress XL gross sales
Individually, Pfizer stated on Monday that it’ll discontinue the advertising, distribution and sale of Minipress XL in India with impact from September 7, 2026.
The choice follows Pfizer Inc.’s resolution to discontinue the manufacture of Minipress XL, Pfizer Ltd stated in an trade submitting.
In reference to the discontinuation, Pfizer Ltd will obtain a lump-sum fee of $13.9 million, or roughly ₹131.38 crore, from Pfizer Inc. USA.
Shares of Pfizer had been buying and selling 0.8% decrease at ₹4,572.70 apiece on the NSE at 11:45 am on Monday.
Novartis India stated the transaction just isn’t a related-party transaction and that Pfizer Inc and Pfizer Merchandise Inc will not be associated to the corporate’s promoter, promoter group or group corporations.
Dr Reddy’s ends Novartis India pact
Final month, Dr Reddy’s Laboratories terminated its distribution and promotion agreement with Novartis India for choose manufacturers in India following a change within the controlling shareholding of Novartis India.
The settlement, initially signed on February 11, 2022, coated the distribution and promotion of choose manufacturers within the home market. Dr Reddy’s stated it will, nevertheless, proceed to commercialise the manufacturers coated beneath the settlement till September 30, 2026.
Shares of Novartis India had been buying and selling 2.9% increased at ₹1,683.35 apiece on the BSE at 11:45 am on Monday. The inventory has superior about 68% up to now in 2026.
Additionally Learn: NSE IPO could raise up to ₹30,000 crore through 6% dilution, sources say: All you need to know
